December 19, 2007 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and MedImmune, Inc. announced that the companies have initiated the Phase 2 portion of a Phase 1/2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) ...
The goal of this open-label, multi-center clinical trial is to evaluate the anti-tumor activity of IPI-504 in patients with NSCLC... Infinity 's Press Release - MedImmune's Press Release -
